Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck Drops Development Of Cardiome’s Oral Vernakalant

Mar 20 2012

• By Lisa LaMotta

Related Content

Merck And Cardiome Obtain EU Approval For Vernakalant In Atrial Fibrillation

Sep 02 2010

Multaq REMS May Be Revamped As Label Adds New Risks

Dec 19 2011

Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas

Jul 26 2011

Related Companies

Cardiome Pharma Corp.

Merck & Co., Inc.

Astellas Pharma, Inc.

Sanofi

Additional Topics

Deals BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window